These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15756436)

  • 1. Expression of c-kit (CD117) in neuroendocrine tumours--a target for therapy?
    Kostoula V; Khan K; Savage K; Stubbs M; Quaglia A; Dhillon AP; Hochhauser D; Caplin ME
    Oncol Rep; 2005 Apr; 13(4):643-7. PubMed ID: 15756436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
    Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
    Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of KIT expression in human tumors.
    Went PT; Dirnhofer S; Bundi M; Mirlacher M; Schraml P; Mangialaio S; Dimitrijevic S; Kononen J; Lugli A; Simon R; Sauter G
    J Clin Oncol; 2004 Nov; 22(22):4514-22. PubMed ID: 15542802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
    Holtkamp N; Okuducu AF; Mucha J; Afanasieva A; Hartmann C; Atallah I; Estevez-Schwarz L; Mawrin C; Friedrich RE; Mautner VF; von Deimling A
    Carcinogenesis; 2006 Mar; 27(3):664-71. PubMed ID: 16357008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Hotfilder M; Lanvers C; Jürgens H; Boos J; Vormoor J
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):167-9. PubMed ID: 12172985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
    Pauwels P; Debiec-Rychter M; Stul M; De Wever I; Van Oosterom AT; Sciot R
    Histopathology; 2005 Jul; 47(1):41-7. PubMed ID: 15982322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
    Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK
    Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias.
    Blay P; Astudillo A; Buesa JM; Campo E; Abad M; García-García J; Miquel R; Marco V; Sierra M; Losa R; Lacave A; Braña A; Balbín M; Freije JM
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4089-95. PubMed ID: 15217944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
    Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
    J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
    Fiorentini G; Rossi S; Lanzanova G; Biancalani M; Palomba A; Bernardeschi P; Dentico P; De Giorgi U
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):17-20. PubMed ID: 16767900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
    Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
    J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
    Sambol EB; Ambrosini G; Geha RC; Kennealey PT; Decarolis P; O'connor R; Wu YV; Motwani M; Chen JH; Schwartz GK; Singer S
    Cancer Res; 2006 Jun; 66(11):5858-66. PubMed ID: 16740725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kit as a human oncogenic tyrosine kinase.
    Kitamura Y; Hirotab S
    Cell Mol Life Sci; 2004 Dec; 61(23):2924-31. PubMed ID: 15583854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor].
    Gelderblom H; Hogendoorn PC; van der Graaf WT; Verweij J
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2051-5. PubMed ID: 14606351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD117 (c-kit) expression in human hepatocellular carcinoma.
    Becker G; Schmitt-Graeff A; Ertelt V; Blum HE; Allgaier HP
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):204-8. PubMed ID: 17359908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.